Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Interleukin-23 in early disease development in rheumatoid arthritis

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Andersen, T, Hvid, M, Johansen, C, Stengaard-Pedersen, K, Hetland, ML, Hørslev-Petersen, K, Junker, P, Østergaard, M & Deleuran, B 2015, 'Interleukin-23 in early disease development in rheumatoid arthritis' Scandinavian Journal of Rheumatology, vol. 44, no. 6, pp. 438-42. https://doi.org/10.3109/03009742.2015.1033007

APA

Andersen, T., Hvid, M., Johansen, C., Stengaard-Pedersen, K., Hetland, M. L., Hørslev-Petersen, K., ... Deleuran, B. (2015). Interleukin-23 in early disease development in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 44(6), 438-42. https://doi.org/10.3109/03009742.2015.1033007

CBE

Andersen T, Hvid M, Johansen C, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Deleuran B. 2015. Interleukin-23 in early disease development in rheumatoid arthritis. Scandinavian Journal of Rheumatology. 44(6):438-42. https://doi.org/10.3109/03009742.2015.1033007

MLA

Vancouver

Author

Andersen, T ; Hvid, M ; Johansen, C ; Stengaard-Pedersen, K ; Hetland, Merete Lund ; Hørslev-Petersen, K ; Junker, P ; Østergaard, Mikkel ; Deleuran, B. / Interleukin-23 in early disease development in rheumatoid arthritis. In: Scandinavian Journal of Rheumatology. 2015 ; Vol. 44, No. 6. pp. 438-42.

Bibtex

@article{7d02615824d5453c95b9957614c38afe,
title = "Interleukin-23 in early disease development in rheumatoid arthritis",
abstract = "OBJECTIVES: To investigate the levels of interleukin (IL)-23 in patients with early rheumatoid arthritis (eRA) and the effect of anti-tumour necrosis factor (anti-TNF)-α treatment on IL-23 levels.METHOD: Treatment-na{\"i}ve eRA patients from the OPERA cohort were included (n = 151). Patients were randomized to methotrexate (MTX) plus adalimumab (ADA; n = 75) or MTX plus placebo-ADA (PLA; n = 76). Plasma samples were obtained at baseline and at months 3, 6, and 12 together with values for C-reactive protein (CRP), the 28-joint Disease Activity Score based on CRP (DAS28CRP), scores on the Clinical Disease Activity Index (CDAI) and the Simplified Disease Activity Index (SDAI), visual analogue scale (VAS) for pain/fatigue/physician global and total Sharp/van der Heijde score (TSS). IL-23 was measured at each time point.RESULTS: IL-23 levels decreased significantly in the ADA group from 20.6 pg/mL (IQR 13.1-32.7 pg/mL) at baseline to 18 pg/mL (IQR 7.2-25.0 pg/mL) at 12 months (p < 0.01). No significant decrease in IL-23 level was observed in the PLA group. No associations between baseline IL-23 levels and measures of disease activity (DAS28CRP, CRP, CDAI, or SDAI) at 12 or 24 months were present in the treatment groups. Baseline IL-23 correlated inversely with changes in TSS and symptom duration before diagnosis.CONCLUSIONS: Our data show increased baseline levels and a significant decrease in IL-23 levels in eRA patients treated with anti-TNF-α. The inverse correlation with duration of symptoms before diagnosis supports the importance of IL-23 in the preclinical disease development of RA.",
author = "T Andersen and M Hvid and C Johansen and K Stengaard-Pedersen and Hetland, {Merete Lund} and K H{\o}rslev-Petersen and P Junker and Mikkel {\O}stergaard and B Deleuran",
note = "COPECARE",
year = "2015",
doi = "10.3109/03009742.2015.1033007",
language = "English",
volume = "44",
pages = "438--42",
journal = "Scandinavian Journal of Rheumatology",
issn = "0300-9742",
publisher = "Informa Healthcare",
number = "6",

}

RIS

TY - JOUR

T1 - Interleukin-23 in early disease development in rheumatoid arthritis

AU - Andersen, T

AU - Hvid, M

AU - Johansen, C

AU - Stengaard-Pedersen, K

AU - Hetland, Merete Lund

AU - Hørslev-Petersen, K

AU - Junker, P

AU - Østergaard, Mikkel

AU - Deleuran, B

N1 - COPECARE

PY - 2015

Y1 - 2015

N2 - OBJECTIVES: To investigate the levels of interleukin (IL)-23 in patients with early rheumatoid arthritis (eRA) and the effect of anti-tumour necrosis factor (anti-TNF)-α treatment on IL-23 levels.METHOD: Treatment-naïve eRA patients from the OPERA cohort were included (n = 151). Patients were randomized to methotrexate (MTX) plus adalimumab (ADA; n = 75) or MTX plus placebo-ADA (PLA; n = 76). Plasma samples were obtained at baseline and at months 3, 6, and 12 together with values for C-reactive protein (CRP), the 28-joint Disease Activity Score based on CRP (DAS28CRP), scores on the Clinical Disease Activity Index (CDAI) and the Simplified Disease Activity Index (SDAI), visual analogue scale (VAS) for pain/fatigue/physician global and total Sharp/van der Heijde score (TSS). IL-23 was measured at each time point.RESULTS: IL-23 levels decreased significantly in the ADA group from 20.6 pg/mL (IQR 13.1-32.7 pg/mL) at baseline to 18 pg/mL (IQR 7.2-25.0 pg/mL) at 12 months (p < 0.01). No significant decrease in IL-23 level was observed in the PLA group. No associations between baseline IL-23 levels and measures of disease activity (DAS28CRP, CRP, CDAI, or SDAI) at 12 or 24 months were present in the treatment groups. Baseline IL-23 correlated inversely with changes in TSS and symptom duration before diagnosis.CONCLUSIONS: Our data show increased baseline levels and a significant decrease in IL-23 levels in eRA patients treated with anti-TNF-α. The inverse correlation with duration of symptoms before diagnosis supports the importance of IL-23 in the preclinical disease development of RA.

AB - OBJECTIVES: To investigate the levels of interleukin (IL)-23 in patients with early rheumatoid arthritis (eRA) and the effect of anti-tumour necrosis factor (anti-TNF)-α treatment on IL-23 levels.METHOD: Treatment-naïve eRA patients from the OPERA cohort were included (n = 151). Patients were randomized to methotrexate (MTX) plus adalimumab (ADA; n = 75) or MTX plus placebo-ADA (PLA; n = 76). Plasma samples were obtained at baseline and at months 3, 6, and 12 together with values for C-reactive protein (CRP), the 28-joint Disease Activity Score based on CRP (DAS28CRP), scores on the Clinical Disease Activity Index (CDAI) and the Simplified Disease Activity Index (SDAI), visual analogue scale (VAS) for pain/fatigue/physician global and total Sharp/van der Heijde score (TSS). IL-23 was measured at each time point.RESULTS: IL-23 levels decreased significantly in the ADA group from 20.6 pg/mL (IQR 13.1-32.7 pg/mL) at baseline to 18 pg/mL (IQR 7.2-25.0 pg/mL) at 12 months (p < 0.01). No significant decrease in IL-23 level was observed in the PLA group. No associations between baseline IL-23 levels and measures of disease activity (DAS28CRP, CRP, CDAI, or SDAI) at 12 or 24 months were present in the treatment groups. Baseline IL-23 correlated inversely with changes in TSS and symptom duration before diagnosis.CONCLUSIONS: Our data show increased baseline levels and a significant decrease in IL-23 levels in eRA patients treated with anti-TNF-α. The inverse correlation with duration of symptoms before diagnosis supports the importance of IL-23 in the preclinical disease development of RA.

U2 - 10.3109/03009742.2015.1033007

DO - 10.3109/03009742.2015.1033007

M3 - Journal article

VL - 44

SP - 438

EP - 442

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

SN - 0300-9742

IS - 6

ER -

ID: 46255232